MENU

Alexander Kutikov, MD, FACS

A. Kutikov, MD, FACS

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Chief, Division of Urology and Urologic Oncology

Professor, Department of Surgical Oncology

Kidney, Bladder, and Prostate Cancer TRDG Member

American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member

Treatment Focus

Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.

Research Program

Key Awards

Philadelphia Magazine Top Docs 2018
     Urology

Language(s) Other than English

Russian

Treatment Philosophy

I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.

When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.

As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.

Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.

Education and Training

Educational Background

  • Fellow, Society of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Chief Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2007-2008
  • Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2004-2007
  • MD, Harvard Medical School, Harvard-MIT Health Sciences and Technology Program, Boston, MA, 2003

Certifications

  • American Board of Urology, Board Certified

Memberships

  • Society of Urologic Oncology
  • American Urological Association
  • American College of Surgeons
  • Philadelphia Urological Society

Honors & Awards

  • Everyday Hero Award, Pennsylvania Medical Society (PAMED), 2018
  • Philadelphia Magazine Top Doctors, 2017-18
  • America's Top Doctors®2016-17
  • BJU International Journal Best Mobile App Award for drawMD Urology iPad Application, American Urological Association Meeting, San Diego, CA, 2013
  • Mid-Atlantic AUA Young Investigator Representative to the AUA’s Research Forum, American Urological Association Meeting, Washington, DC, 2011
  • CaPSURE Scholar, CaPSURE Scholars Program in Prostate Cancer Outcomes Research, 2009-10
  • American College of Surgeons Excellence in Research Award 96th Annual Clinical Congress, Surgical Forum, 2010
Patient Stories

Thomas Myers

Melanoma;  Prostate Cancer

Thomas Myers

Melanoma;  Prostate Cancer

The level of teamwork and communication amongst the doctors was reassuring. Even though I felt overwhelmed by multiple surgeries, treatments, and diagnoses, I took immense comfort in the prompt actions taken my team of physicians.

Barry Taitelman

Kidney Cancer

Barry Taitelman

Kidney Cancer

Becoming a grandfather was something I had been looking forward to for years. But just before I learned that my daughter-in-law was pregnant, I was diagnosed with Stage 4 kidney cancer. Instead of the overwhelming joy I had been anticipating, I was wracked with fear. I couldn’t bear the thought of getting to know my grandson and then not getting to be there to watch him grow up.

Joe Briggs

Prostate Cancer

Joe Briggs

Prostate Cancer

After being diagnosed with an aggressive form of prostate cancer, Joe Briggs sought treatment at Fox Chase Cancer Center, where he underwent a robotic prostatectomy. About three months after surgery, he was back to work and spending time with his family. He credits Fox Chase as being oat the forefront of cutting-edge treatment options for cancer. "Looking back, I am confident that Fox Chase was the best place for my care and that it was the best decision that we have made," Joe said. "I feel they are offering world-class treatment 30 minutes from my house. They use cutting-edge treatments that are performed by the brightest minds in health care who care about me and care about my wife and family."

Victoria Mirarchi

Sarcoma

Victoria Mirarchi

Sarcoma

At 81 years old, Victoria Mirarchi was still active and healthy before undergoing surgery at a local hospital to remove a large mass from her abdominal area. The mass was diagnosed as liposarcoma, an aggressive tumor. When the tumor returned twice, Victoria decided to seek a second opinion from the specialists at Fox Chase Cancer Center. Following the surgery at Fox Chase, Victoria is happy to report that the cancer has not returned. She said, "I am so happy everything went well, and I still go back to Fox Chase every few months to see Dr. Reddy. I wish nothing but the best for all the surgeons there, and keep them in my prayers daily."

Arkady Shteyman

Kidney Cancer

Arkady Shteyman

Kidney Cancer

Kidney cancer is something Arkady Shteyman has lived with since 1968. That's the year, when Arkady was 19, that his father died of the disease at the young age of 44.

"Because I have that history, I get regular ultrasounds," said the electronic technician, who immigrated to the Philadelphia region from the Ukraine in the former Soviet Union in 1990.

Pages

Research Profile

Research Program

Research Interests

Dr. Kutikov has authored over 140 peer-reviewed publications.  His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks.  He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.

Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care.  He is a co-founder of several ventures that strive to improve physician education and patient care.  

Lab Overview

In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.

As part of our work, we explore the role of zinc in development and progression of prostate malignancy.  Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.

The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.

In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.

Publications

Selected Publications

Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed

Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo RG, Kolenko VM. The convergent roles of NF-kappaB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell death & disease, 9(3):374, 2018. PMC5841329

Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DYT, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM. Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. JAMA Oncol, 2018. 

S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015.   PubMed

J. J. Tomaszewski, R. G. Uzzo, B. Egleston, A. T. Corcoran, R. Mehrazin, D. M. Geynisman, J. A. Ridge, C. Veloski, N. Kocher, M. C. Smaldone, and A. Kutikov, “Coupling of Prostate and Thyroid Cancer Diagnoses in the United States.,” Ann Surg Oncol, pp. 1–7, Sep. 2014.   PubMed

A. T. Corcoran, S. D. Kaffenberger, P. E. Clark, J. Walton, E. Handorf, Z. Piotrowski, J. J. Tomaszewski, S. Ginzburg, R. Mehrazin, E. Plimack, D. Y. T. Chen, M. C. Smaldone, R. G. Uzzo, T. M. Morgan, and A. Kutikov, “Hypoalbuminemia is Associated with Mortality in Patients Undergoing Cytoreductive Nephrectomy.,” BJU Int, pp. n/a–n/a, Aug. 2014.  

J. J. Tomaszewski, M. C. Smaldone, R. G. Uzzo, and A. Kutikov, “Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephron-sparing surgery?,” BJU Int, pp. n/a–n/a, Aug. 2014.   PubMed

A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014.    PubMed

B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity.,” European Urology, May 2014.   PubMed

S. Ginzburg, R. Uzzo, T. Al-Saleem, E. Dulaimi, J. Walton, A. Corcoran, E. Plimack, R. Mehrazin, J. Tomaszewski, R. Viterbo, D. Y. T. Chen, R. Greenberg, M. Smaldone, and A. Kutikov, “Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy.,” The Journal of Urology, vol. 191, no. 2, pp. 296–300, Feb. 2014.    PubMed

A. Kutikov, B. L. Egleston, D. Canter, M. C. Smaldone, Y.-N. Wong, and R. G. Uzzo, “Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model.,” The Journal of Urology, vol. 188, no. 6, pp. 2077–2083, Dec. 2012.    PubMed

M. C. Smaldone, B. Egleston, R. G. Uzzo, and A. Kutikov, “Does partial nephrectomy result in a durable overall survival benefit in the Medicare population?,” The Journal of Urology, vol. 188, no. 6, pp. 2089–2094, Dec. 2012.    PubMed

A. Kutikov, B. Rozenfeld, B. L. Egleston, M. Sirohi, R. W. Hwang, and R. G. Uzzo, “Academic ranking score: a publication-based reproducible metric of thought leadership in urology.,” European Urology, vol. 61, no. 3, pp. 435–439, Mar. 2012.   PubMed

A. Kutikov, K. Mallin, D. Canter, Y.-N. Wong, and R. G. Uzzo, “Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database.,” The Journal of Urology, vol. 186, no. 3, pp. 805–810, Sep. 2011.    PubMed

A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011.   PubMed

Additional Publications

My NCBI

Ratings

258 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.9
  • 4.9
  • 5.0
  • 5.0
  • 4.8

38 PATIENT COMMENTS

  • 5.0
    September 25, 2018
    I feel as though I am in the best care with Dr. Alexander Kudukov. extremely happy.
  • 5.0
    September 20, 2018
    I have referred friends to Dr. Kutikov, and willl continue to do so.
  • 5.0
    September 20, 2018
    smart, personable, responsive
  • 5.0
    September 02, 2018
    Outstanding!
  • 5.0
    August 23, 2018
    There are other doctors closer to me, but I choose Dr. Kutikov & staff because of their level of expertise & the concern they show for me.
  • 5.0
    August 23, 2018
    Perhaps I am so delighted because my prognosis is good. I have to say that I really love everyone at Fox Chase. I appreciate their skills and their compassion. I feel like I was taken seriously and all my concerns were addressed. Meeting Dr. Kutikov and having chosen him to do my surgery was a truly lucky day in my life.
  • 5.0
    August 23, 2018
    very happy with all services
  • 5.0
    August 21, 2018
    Been going here since 2011 - would not be alive without help of Dr. Kutikov.
  • 5.0
    August 21, 2018
    Good.
  • 5.0
    August 09, 2018
    Dr. Kutikov is the best. I have recommended him to friends dealing with urologic cancer.
  • 5.0
    August 03, 2018
    I was facing cancer and was very concerned. The Doctor was very informative and positive about my situation and that made me feel at ease. I did have some follow up questions and called the office to ask, the doctor called me back in less than 45 minutes. I must say I was taken back by his promptness. I expected a call the next day.
  • 5.0
    August 01, 2018
    Best surgeon ever. I have full confidence in him.
  • 5.0
    July 21, 2018
    Altho very busy, once he came into the room I was treated as tho I were his only patient! One of the best physicains I have ever had!
  • 5.0
    June 24, 2018
    Dr. Kutikov is the best doctor I have ever dealt with. Courteous, caring, genuine and very good at what he does. I have recommended him to many!
  • 5.0
    June 19, 2018
    Excellent
  • 5.0
    June 17, 2018
    Kutikov is VERY impressive!!
  • 5.0
    June 07, 2018
    Dr Kutakov seemed very kind and concerned for my illness. I felt I could trust him with my care.
  • 5.0
    May 31, 2018
    This provider is not only highly skilled but also very compassionate. A rare gem in this medical field.
  • 5.0
    May 31, 2018
    professional and understanding to my needs
  • 5.0
    May 29, 2018
    I have the utmost respect for Dr. Kutikov and trust him with my cancer treatments.
LOAD MORE

Connect with Fox Chase